Study findings shed light on effective new HCV therapy that will treat patients who have failed other therapies
San Antonio, Texas – April 27, 2017 – (Newswire.com)
Dr. Fred Poordad, internationally recognized for his research in the field of liver diseases, presented a retreatment study of patients who have failed to be cured with current hepatitis C therapy, achieving over 90% response rates in the most commonly found treatment failure patients. Dr. Poordad spoke on the study findings at The International Liver Congress™ 2017, presented by the European Association for the Study of Liver (EASL). The study was performed at the American Research Corp at the Texas Liver Institute, a world-renowned facility for liver research and the prevention and treatment of liver disease.
Dr. Poordad presented data on 91 patients who had failed to be cured by currently approved therapies. In some cases, the patients had failed numerous HCV therapies over multiple years.